Swedish Orphan Biovitrum AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Swedish Orphan Biovitrum AB
The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.
GlaxoSmithKline's first-of-its kind treatment for multiple myeloma is among 11 new medicines that have won an EU approval nod from the European Medicines Agency this week.
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Akinion Pharmaceuticals AB
- Arexis AB
- Biovitrum AB
- Dova Pharmaceuticals, Inc.
- Sobi, Inc.
- Swedish Orphan International Holding AB